Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …

The Swiss HIV Cohort Study (SHCS) provides a unique research platform for clinical,
translational, epidemiological, social and basic research. The SHCS was established in …

Highlights•Broadly neutralizing antibodies are promising for HIV-1 prevention and
therapy.•Newly identified bNAbs reveal novel epitopes and binding modes.•Effective …

A successful HIV-1 vaccine will require induction of a polyclonal neutralizing antibody (nAb)
response, yet vaccine-mediated induction of such a response in primates remains a …

Recognition of cell-surface receptors and co-receptors is a crucial molecular event towards
the establishment of HIV infection. HIV exists as several variants that differentially recognize …

Determining which immunological mechanisms contribute to the development of broad
neutralizing antibodies (bNAbs) during HIV-1 infection is a major goal to inform vaccine …

Broadly neutralizing antibodies (bnAbs) develop in a subset of HIV-1 infected individuals
over 2–3 years of infection. Infected infants develop plasma bnAbs frequently and as early …

The HIV-1 pandemic remains a major burden on global public health and a vaccine to
prevent HIV-1 infection is highly desirable but has not yet been developed. Among the many …

With the much-debated exception of the modestly reduced acquisition reported for the
RV144 efficacy trial, HIV-1 vaccines have not protected humans against infection, and a …

The V3 loop of the HIV-1 envelope (Env) protein elicits a vigorous, but largely non-
neutralizing antibody response directed to the V3-crown, whereas rare broadly neutralizing …